Big opportunities in emerging health care companies often come with very bumpy rides. There is also the risk, of course, that there are no assurances that the potential promise and upside will come true…
Ionis Pharmaceuticals saw its shares pullback on Monday morning after results were released from its late-stage trial for the treatment of familial amyloid polyneuropathy.
G1 Therapeutics expects to offer more than 6 million shares in the range of $15 to $17 apiece in an initial public offering valued up to around $122 million.
It is no secret that pharma and biotech shares have had to deal with at least some headwinds over the past year. It turns out that drug pricing concerns and political oversight can still…
The April 28 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mostly downward.
The analysts at Stifel have focused on biotech and specialty pharma companies that not only have data that could prove to be huge, but they are offering aggressive accounts the best entry points in…
With earnings this positive and shares responding as a result, investors have to wonder if Valeant Pharmaceuticals is for real this time, or is this just a head fake.